Rivastigmine

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cognitive Symptoms

Conditions

Cognitive Symptoms

Trial Timeline

Jan 1, 2003 → May 1, 2004

NCT ID

NCT00134953

About Rivastigmine

Rivastigmine is a phase 3 stage product being developed by Novartis for Cognitive Symptoms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00134953. Target conditions include Cognitive Symptoms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00000174	Phase 3	Completed	—	—	Alzheimer Disease
NCT02989402	Approved	Completed	Dec 31, 2018	Dec 8, 2022	Alzheimer's Disease
NCT02063269	Pre-clinical	UNKNOWN	Feb 1, 2014	Jun 1, 2017	Alzheimer's Disease
NCT00104442	Approved	Completed	Oct 1, 2003	Apr 1, 2006	Alzheimer's Disease
NCT00134953	Phase 3	Terminated	Jan 1, 2003	May 1, 2004	Cognitive Symptoms
NCT00171795	Phase 3	Completed	Nov 1, 2002	May 1, 2005	Traumatic Brain Injury
NCT00219245	Approved	Completed	Nov 1, 2002	Jan 1, 2005	Traumatic Brain Injury With Persistent Cognitive Deficits
NCT00130338	Phase 3	Completed	Feb 1, 2002	May 1, 2006	Vascular Dementia
NCT00099216	Phase 3	Completed	Aug 1, 2001	Nov 1, 2005	Vascular Dementia

Competing Products

20 competing products in Cognitive Symptoms

See all competitors

Product	Company	Stage	Hype Score
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	85
Donepezil	Eisai	Approved	85
Aricept	Eisai	Phase 2	52
Donanemab + Aducanumab	Eli Lilly	Phase 3	77
ABT-126 + Placebo	AbbVie	Phase 2	52
SDI-118 + Placebo	AbbVie	Phase 1	33
ABT-288 Low Dose + Placebo + ABT-288 High Dose	AbbVie	Phase 2	52
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	52
MK-8931	Merck	Phase 1	33
Nicotine patch + MK-4334 + Placebo patch + Placebo capsule	Merck	Phase 1	33
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	77
Rivastigmine	Novartis	Approved	85
Exelon (rivastigmine) + Placebo	Novartis	Approved	85
Canakinumab	Novartis	Phase 2	52
Eviplera	Gilead Sciences	Approved	84
atorvastatin	Pfizer	Pre-clinical	22
bosutinib	Pfizer	Phase 1	32
Aducanumab + Placebo	Biogen	Phase 2	49
BIIB080 + BIIB080-matching placebo	Biogen	Phase 2	49
BIIB104	Biogen	Phase 2	49

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved